Systematic Review of Tongxinluo Capsule on the Therapeutic Effect and Hemorheology of Patients with Transient Ischemic Attack

Abstract

Objectives. This study aims to systematically evaluate the clinical efficacy of Tongxinluo capsule in the treatment of transient ischemic attack (TIA) and its effect on hemorheology, thereby providing scientific basis for clinical decision making. Methods. A comprehensive and systematic literature retrieval was conducted in the CNKI, Wanfang database, SinoMed, EMbase, and PubMed to screen the randomized controlled trials (RCTs) of Tongxinluo capsule in the treatment of TIA. The retrieval time was from the inception of each database to September 10, 2020. Endnote X9 was used to screen the literature. Cochrane Collaboration tool for assessing risk of bias was used to evaluate the quality of the included studies. Stata16.0 statistical software was used for meta-analysis. Results. A total of 12 RCTs were included, involving 946 subjects. (1) The clinical efficacy of the Tongxinluo group was better than that of the control group (RR = 1.19, 95% CI (1.09, 1.30), P ≤ 0.001). (2) The hemorheological characteristics of the Tongxinluo group were significantly improved compared with those of the control group (whole blood high shear viscosity: SMD = −1.61, 95% CI (−1.89, −1.34); P ≤ 0.001, whole blood low shear viscosity: SMD = −1.06, 95% CI (−1.31, −0.80), P ≤ 0.001, fibrinogen: SMD = −1.12, 95% CI (−1.94, −0.29), P = 0.008, plasma specific viscosity: SMD = −1.00, 95% CI (−1.69, −0.31), P = 0.004, and hematocrit: SMD = −1.47, 95% CI (−2.16, −0.77), P ≤ 0.001). (3) There was no significant difference in the incidence of adverse reactions between the Tongxinluo group and control group (RR = 7.76, 95% CI (0.98, 61.28), P = 0.052). Conclusion. Tongxinluo capsule is superior to conventional treatment in improving clinical overall response rate and hemorheological indexes and is relatively safe. Due to the deficiencies of the existing studies, more high-quality studies with rigorous design are required for further verification.

Protective effe cts and potential mechanism of To ngxinluo on mouse with thromboangiitis obliterans

“…A recent study found that TXL reduced inflammation and enhanced the stability of atherosclerotic plaques by regulating intestinal flora [12] . Other studies found that TXL significantly reduced plasma viscosity and improve the indexes of hemorheology in patients [13] . These studies all further confirm the anti-inflammatory and antithrombotic properties of TXL.…”

Recent advances in Chinese patent medicines entering the international market

“…Moreover, Tongxinluo capsules combined with atorvastatin effectively improved the clinical treatment of CHD, significantly reduced the frequency and duration of angina pectoris, decreased blood lipids, and improved inflammatory factors (53). In addition, the addition of Tongxinluo capsules to routine medication was beneficial to the treatment of a transient ischemic attack (TIA), significantly improving clinical efficacy and hemorheological characteristics, reducing blood viscosity, and promoting microcirculation (54).…”

A case report of effective treatment of diabetic foot with the integration of traditional Chinese medicine and western medicine

“…Moreover, the patient was given oral atorvastatin tablets (20mg/day) for lipid regulation and plaque stabilization, oral aspirin (100mg/day) for antiplatelet coagulation, and ceftriaxone injections for anti-infection, according to the Chinese guidelines for the prevention and treatment of diabetic foot [ 7 ]. In terms of TCM treatment, the patient was given oral Chinese medicine compound Tongxinluo (TXL, 4 capsules/time, 3 times/day) to tonify Qi, nourish Yin and promote circulation [ 8 ]. In addition, medium-frequency pulsed electrical therapy was performed on the patient's bilateral Quchi (LI 11) and Tsusanli (ST 36) to unblock the collaterals and relieve pain [ 9 ].…”